Introduction
There is recent appreciation that the host response to infections and insults is tightly regulated with the engagement of a series of lipid mediators, cytokines, and adhesion molecules to promote extravasation, immune cell trafficking, and removal of pathogen.
1,2 These events are followed by release of other mediators that quench these processes, stopping cell trafficking, promoting apoptosis and efferocytosis of extravasated cells, and leading to tissue repair. 3 Effectors of resolution ensure that this response remains localized within the inflamed tissue site and it is extinguished within an adequate timeline. The glucocorticoid cortisol exerts a central role in resolution or, in more general terms, on the host defense response in stress conditions. 4 In a homeostatic fashion, there is appreciation that "…the beginning programs the end," and therefore the proinflammatory phase induces resolution, to assure a strict, temporally and spatially regulated response. 5 Within the context of resolution, a prominent role is played by rapidly produced lipid mediators, such as 5S,6R,15S-trihydroxyl-7,9,13-trans-11-cis-eicosatetraenoic acid (lipoxin A 4 [LXA 4 )]) or resolvins 6 as well as proteins including erythropoietin and Annexin A1 (AnxA1). In particular, LXA 4 and AnxA1 are prototypes of proresolving mediators in view of their different nature (lipid vs protein), mode of activation (transcellular biosynthesis vs cytoplasmic pools mobilization), and engagement by widely used therapeutics (aspirin [ASA] for LXA 4 or glucocorticoids for AnxA1). However, they are also interconnected by sharing the G protein-coupled receptor FPR2/ ALX (formyl-peptide receptor type 2 or LXA 4 receptor; termed Fpr2/3 in the mouse). 7, 8 Although inflammation is a life-saving process and must be highly efficient against bacteria invasion, "inflammation from within"-that is, in the vasculature-must be tightly controlled to avoid widespread damage. Thus, low doses of LXA 4 inhibit polymorphonuclear cells (PMN) accumulation both in postischemic mesenteric tissues 9, 10 and in distant organs such as the lung 11 ; similarly, AnxA1 and erythropoietin are potent inhibitors of myocardial infarct, stroke, and vascular reperfusion injury. [12] [13] [14] In situations where reperfusion occurs, such as renal transplantation, LXA 4 15 and resolvins 16 are highly protective, and the same has been reported recently for AnxA1 mimetics. 17 Here we compared vascular inflammation indexes in wild-type and Fpr2/3 2/2 mice, 18 uncovering a novel vasculo-protective pathway centered on LXA 4 . During the ischemic phase, platelet/neutrophil aggregates are formed, affording transcellular biosynthesis of this bioactive lipid. This process is also activated by low-dose ASA administration. Intravital microscopy after ischemia-reperfusion in mouse mesenteric microcirculation
Material and methods

Animals
Intravital microscopy was performed as previously reported. 10, 19 Mice were anesthetized and placed in the supine position on a heating pad (37°C). Mesenteric ischemia was induced with a microaneurysm clip (Harvard Apparatus, Kent, UK), clamping the superior mesenteric artery for 30 minutes. The clip was then removed, and reperfusion was allowed for between 45 and 180 minutes. Sham-operated animals underwent the same surgical procedure except for the clamping of the superior mesenteric artery.
The vascular bed was exposed and positioned under the microscope; recording started after a 5-minute equilibration period, followed by offline analyses, as reported. 10, 19 These were made in 1 to 3 randomly selected postcapillary venules (diameter, 20-40 mm; visible length >100 mm) for each mouse. Thus, rolling leukocyte flux was obtained by the number of leukocytes passing a reference point in the venule per minute (cells/minute); leukocyte adhesion reflected cells stationary for 30 seconds or longer; leukocyte emigration was calculated by the number of cells in a 100 3 50 mm 2 area on both sides of the 100-mm vessel segment. For all vessels, red blood cell centerline velocity was measured with an optical Doppler velocimeter (Microcirculation Research Institute, Texas A&M University, Dallas, TX) and venular wall shear rate was determined based on the Newtonian definition: wall shear rate 5 8000 [(red blood cell velocity/1.6)/venular diameter].
Confocal imaging protocol
Immunofluorescence staining of whole mesentery was carried out on tissues fixed in paraformaldehyde 4% for 15 minutes blocked for 1 hour in phosphatebuffered saline containing 1% Triton X-100, 1% bovine serum albumin, and 3% natural goat serum, and washed 3 times. Incubation with specific antibodies for vascular endothelium (clone BV14, eBioscience, Hatfield, UK), neutrophils (clone MRP14-647, in-house labeled), and/or monocytes/macrophages (CD115, AFS98, Biolegend, London, UK) was followed by extensive washes in phosphate-buffered saline and mounted on polylysine-coated slides (Invitrogen, Paisley, UK). Confocal images were analyzed using a Zeiss LSM5 PASCAL confocal laser-scanning microscope (Zeiss, Welwyn Garden City, UK).
Assessment of platelet/neutrophil aggregates in mouse blood
Whole blood flow cytometry was performed to quantify the extent of neutrophil/platelet complexes in blood taken from mice after ischemiareperfusion (IR), ischemia alone, or sham procedure. Blood aliquots (collected in Hirudin prefilled blood tubes, Dynabyte GmbH, Munich, Germany) were stained with Ly6G-APC (clone RB6-8C5, 1 mg/mL; eBioscience) to identify neutrophils and CD41-PE (MWReg30, 1 mg/mL; eBioscience) to identify platelets. Red blood cells were then lysed, and cell pellet was washed and fixed before sample analysis with a FACScalibur flow cytometer (BD Bioscience, Oxford, UK) acquiring >10 000 events. Scatter plot analysis identified the neutrophil population (.95% Ly6G1), and the extent of CD41-positive events therein was then quantified. Results are reported as percentage of Ly6G1/CD411 (double positive) events.
Chimeric experiment: platelet labeling and reinfusion
Blood from a donor mouse was withdrawn in syringes prefilled with 85 mM sodium citrate, 62.2 mM citric acid, and 110 mM glucose (ACD buffer; SigmaAldrich, St. Louis, MO). Platelet-rich plasma was obtained by centrifugation (118 3 g, 8 minutes) before platelet isolation by centrifugation at 735 g for 10 minutes. Platelets were gently resuspended, counted, and labeled by using carboxyfluorescein succinimidyl ester (CFSE, 90 mM; 10 minutes). After confirming absence of aggregates by light microscopy, 100 3 10 6 platelets in 120 mL were injected through the jugular vein of a recipient mouse over 5-minute infusion. The animal was then rested for 5 minutes to allow platelet circulation before starting experiment (ischemia or sham procedure) as described previously.
Pharmacological treatments
Different compounds were administered as tools to define specific biochemical pathways.
MPBiomedicals, Cambridge, UK) was given intravenously via the jugular vein before ischemia or immediately before reperfusion, at 10 mg per mouse. 10 LXA 4 was injected before ischemia at doses of 1-100 ng per mouse, as informed from previous experiments. 10, 13 In a separate set of experiments, mice were treated with anti-inflammatory doses of ASA (30-300 mg/kg intraperitoneally; Sigma-Aldrich) or indomethacin (0.3-3 mg/kg intraperitoneally, Sigma-Aldrich) 20 given before the IR procedure.
Determination of plasma mediator levels
Enzyme-linked immunosorbent assays. LXA 4 and 5S,6R,15R-trihydroxyl-7, 9,13-trans-11-cis-eicosatetraenoic acid (15-epi-LXA 4 ) were assayed using ELISA kit purchased from Neogen Corporation. Lipid extraction and determination were carried out according manufacturer's specifications. Thromboxane A 2 and prostacyclin formation were quantified with enzyme immunoassay measuring their stable analogs Thromboxane B 2 (R&D Systems) and 6-keto-prostaglandin F1a (Cayman Chemicals). Mouse serum amyloid protein A (SAA) levels were determined by using specific kit from Immunology Consultants Laboratory Inc. A linear regression with a weight factor of 1/X was applied for each compound. By the use of this factor, a calibration line with a coefficient of correlation .0.998 and an accuracy ranging from 85% to 115% was obtained. The limit of detection and the limit of quantification were determined for the 13 compounds using signal-to-noise ratio. All values under the limit of quantification were not considered. Blank samples were also evaluated, and their injection showed no interference (no peak detected) during the analysis.
Statistics
All results are reported as mean 6 SEM of n distinct observations. Differences between 2 groups were determined with the Student t test; more than 2 groups were analyzed by analysis of variance upon satisfaction of homogeneity of variances. Intergroup analyses were assessed with the Dunnett or Bonferroni tests, as appropriate. In all cases, P , .05 was taken as significant to reject the null hypothesis.
Results
Intravital microscopy analysis of IR injury in the Fpr2/3 2/2 mesenteric microcirculation Clamping of the superior mesenteric artery for 30 minutes, followed by reperfusion, provoked a time-dependent vascular inflammatory response. As expected, rapid induction of cell flux occurred at 45 minutes after reperfusion, with no statistical difference between Fpr2/3 1/1 and Fpr2/3 2/2 mice (not shown). This was followed by a robust cell adhesion response that was significantly exacerbated in Representative images of postcapillary venules are shown in Figure 1C -H. Noninflamed vessels in sham mice (panels C and D) and marked accumulation of leukocytes in mice subjected to IR at 90 minutes after reperfusion, with higher counts observed in Fpr2/3 2/2 mice (P , .01) (supplemental Figure 1 : images at 45-180 minutes after reperfusion). These leukocytes were all neutrophils, as demonstrated by specific staining for MRP14 using confocal microscopy ( Figure 1D ). CD115 staining was also performed to identify activated monocytes, but this cell type was not detected at any of the time points analyzed (data not shown). Supplemental Table 1 summarizes the hemodynamic parameters measured in these microvascular beds, indicating no major changes between genotypes. mice with the Fpr2/3 antagonist Boc2 before, but not after, ischemia unveiled a phenotype in Fpr2/3 1/1 mice similar to that of Fpr2/3
mice, that is an increase in the extent of neutrophil adhesion (not shown) and emigration ( Figure 2C ). Boc2 did not modify the cellular response in Fpr2/3 2/2 mice ( Figure 2C ). These results indicate that Fpr2/3 controls vascular reactivity to ensure adequate counterregulation of the inflammatory response during IR of the mesenteric microcirculation. ) mice were subjected to 30 minutes' clamping of the superior mesenteric artery, followed by a reperfusion phase lasting 45 to 180 minutes. Postcapillary venules were imaged and recorded for offline quantitation of white blood cell interaction with the endothelium. In parallel experiments, tissue was excised and analyzed by confocal microscopy. Green, vessel vascular endothelium staining; blue, neutrophil MRP14 marker. Data are mean 6 SEM of 6 to 8 mice per group. *P , .05, **P , .01 vs respective Fpr2/3 1/1 value.
Next, we monitored endogenous generation of Fpr2/3 agonists including the anti-inflammatory and pro-resolving lipid mediator LXA 4 and the pro-inflammatory agonist SAA. Enzyme-linked immunoassay analysis indicated significant changes in plasma LXA 4 levels (;twofold increase) in Fpr2/3 1/1 mice after 30 minutes of ischemia ( Figure 2D ). This early modulation did not occur in either Fpr2/3 2/2 or Fpr2/3 1/1 mice treated with Boc2, in which LXA 4 plasma levels were elevated solely after 90 minutes of reperfusion ( Figure 2D ). In comparison, levels of SAA levels did not change during the course of the IR procedure in either of the mouse genotypes (supplemental Figure 2) . LC/MS/MS-based lipidomic analysis was performed to afford multiple lipid determination. Changes in LXA 4 plasma levels were unequivocally determined by chromatography peak identification and diagnostic fragments ( Figure 3A) . Quantification of these results demonstrated a substantial increase in LXA 4 at after 30 minutes' ischemia in Fpr2/3
, but not Fpr2/3 2/2 , mice ( Figure 3B ). Interestingly, lipoxin B 4 (LXB 4 ), 5-HETE, 12-HETE, and LTB 4 plasma levels did not change upon ischemia ( Figure 3B ). In contrast, 15-HETE was significantly elevated, but this increment occurred in both genotypes ( Figure 3B) .
A closer assessment of these findings revealed a significant negative correlation between postischemic plasma LXA 4 concentrations and the extent of emigrated cells 90 minutes after reperfusion (supplemental Figure 3) . Delivery of Boc2 to block endogenous Fpr2/3 disrupts the process(es) leading to LXA 4 biosynthesis, abrogating this correlation (supplemental Figure 3) .
Evidence of platelet/neutrophil aggregate formation during ischemia A major biosynthetic pathway for LXA 4 within the vasculature occurs by the concerted action of platelet 12/15 lipoxygenase and neutrophil 5-lipoxygenase 21 ; hence, we questioned whether the differences in LXA 4 biosynthesis could be due to differences in the number of platelet/neutrophil aggregates forming during ischemia.
We used a flow cytometry-based approach to study the granulocyte population in whole blood (see scattering dot plot in supplemental Figure 4) . Using a specific antibody against Ly6G or CD41 to identify PMN or platelets, respectively, aggregate animals. Next, we determined if vasculoprotective drugs could use this novel circuit. Here we tested the actions of ASA, which has been shown to trigger the biosynthesis of a LXA 4 epimer, 22 and indomethacin, which does not. Treatment of mice with ASA (30-300 mg/kg) produced a dosedependent inhibition of vascular inflammation as measured 90 minutes after reperfusion ( Figure 5 ). Although the top dose of 300 mg/kg was equally active in Fpr2/3 2/2 mice, lower doses of 30 and 100 mg/kg ASA were no longer able to inhibit cell adhesion ( Figure 5A ) or emigration ( Figure 5B ) in Fpr2/3 2/2 mice. Indomethacin markedly inhibited white blood cell interaction with post-capillary venules in both genotypes, as quantified by intravital microscopy (supplemental Figure 5 ). By acetylating the catalytic site of cyclo-oxygenase, ASA blocks the conversion of arachidonic acid into prostaglandins but leads instead to the generation of epi-LXA 4 which triggers pro-resolving responses through engagement of Fpr2/3. 7 To ascertain whether this mechanism operated in our model, we measured plasma lipid mediators in mice treated with ASA (Table 1) . IR augmented levels of thromboxane A 2 (measured as its stable metabolite TXB 2 ) and prostacyclin compared with sham mice; ASA (100 mg/kg) attenuated this response. The effect was also present in Fpr2/3 2/2 mice, indicating that it is independent from platelet/neutrophil aggregates and, rather, functionally related to cyclo-oxygenase blockade. We could not detect 15-epi-LXA 4 in vehicle-treated mice, with or without IR, but this LXA 4 epimer was measured in both genotypes upon treatment with ASA (Table 1) . Therefore, at appropriate doses, ASA induces biosynthesis of an Fpr2/3 agonist, which attenuates vascular inflammation in Fpr2/3 1/1 but not Fpr2/3 2/2 mice.
Discussion
Appreciation of the homeostatic functions of pro-resolving and tissue protective mediators and pathways is emerging in the context of immune responses ranging from colitis to joint disease, from ocular to periodontal pathologies. 3 However, relevance of these effectors of resolution in vascular damage is scantily investigated.
This study originated from the observation that Fpr2/3 2/2 mice experience more aggressive neutrophil trafficking in postcapillary venules in mesenteric IR. This led us to unveil an endogenous protective signal, mediated by neutrophil Fpr2/3, controlling aggregate formation with platelets in the bloodstream. The end point consists in For personal use only. on January 17, 2018. by guest www.bloodjournal.org From the generation of LXA 4 that would then limit the degree of vascular inflammation. In absence of Fpr2/3, the fine-tuning exerted by this novel circuit is lost, leading to excessive vascular inflammation and potential tissue injury. Figure 6 schematizes these novel findings.
LXA 4 was identified by Serhan and colleagues in the late 1980s, 23 whereas ASA-triggered lipid mediators were discovered later 22, 24 ; these intriguing autacoids are formed by transcellular biosynthesis in which a first enzyme/cell generates an intermediate product used as substrate by a second enzyme/cell. In the mouse, 1 such pathway leading to LXA 4 biosynthesis is through the concerted action of neutrophils and platelets, providing the 5-lipoxygenase and the 12/15-lipoxygenase (2 distinct enzymes in the human system), respectively 21 (see Figure 6 for scheme). We demonstrate here that during mesenteric IR, this biosynthetic pathway is activated. In particular, platelet/neutrophil aggregation would "provide the machinery" for generation of LXA 4 during ischemia; it is plausible that during reperfusion, the endothelial cell/neutrophil pair (recently reviewed by Eltzschig and Eckle 25 ) will support and expand the biosynthesis of these lipids. In our experimental settings, the leukocyte involved is the neutrophil and we could not detect trafficking of inflammatory monocytes (or any other bloodborne cell) within the applied timeframe.
The present project began by assessing if Fpr2/3 had any functional relevance in IR. In sterile inflammation, this receptor is the main transducer of the pro-resolving actions of LXA 4 and AnxA1. Pharmacological delivery of either mediator engages Fpr2/3 to activate circuits of resolution, including attenuation of leukocyte trafficking, 18 promotion of apoptosis, 26 and efferocytosis, 27, 28 favoring egress of leukocyte from the tissue. 29 Attenuation of postischemic leukocyte recruitment is crucial to prevent vascular and parenchymal damage as shown in many experimental settings in animals and also in human intestine, where removal of neutrophils for perfusates yielded consistent diminution of tissue injury. 30 Pro-resolving processes have been detailed, mostly, in experimental models of tissue inflammation, including peritonitis, pleurisy, and dorsal air pouches, with important confirmation in experimental and human colitis. 31, 32 More recent studies have corroborated these pharmacological findings with investigations in transgenic mice, including AnxA1 . We measured consistent increases in LXA 4 levels during ischemia, with marked amounts seen after reperfusion. SAA levels did not change during the time course of our experiments and remained relatively constant to sham concentration in the 2 genotypes. AnxA1 could not be measured in the plasma, because in the presence of a high calcium concentration, it associates with cell plasma membranes. 36 Interestingly, following the clamping and reopening of the superior mesenteric artery in AnxA1 2/2 mice, we did not detect differences in platelet/neutrophil aggregate formation (at the end of ischemia) or leukocyte/endothelium interaction (up to 180 minutes after reperfusion; data not shown).
The positive association between postischemia LXA 4 and the extent of vascular reactivity after reperfusion emerged on several levels. First, there was a highly significant negative correlation between plasma concentration of this bioactive lipid during ischemia and extent of neutrophil adhesion and emigration; second, when a comparison between Fpr2/3 1/1 and Fpr2/3 2/2 was conducted, lack of LXA 4 biosynthesis in the null mouse led to marked inflammation. Finally, administration of Boc2 preischemia abrogated the production of endogenous LXA 4 with consequent downstream imbalance in vascular reactivity. The augmented LXA 4 levels measured postischemia are likely, though not solely, the result of formation of platelet/neutrophil aggregates and cell-to-cell crosstalk necessary to bring in close proximity the biosynthetic machinery required for its generation. 37 The data obtained with the chimeric experiments suggest that this ) mice were subjected to 30 minutes' clamping of the superior mesenteric artery, followed by a 90-minute reperfusion phase. Mice received vehicle (1 mL/kg) or the reported doses of ASA intraperitoneally 30 minutes before ischemia. Bars report the number of neutrophils adherent (A) or emigrated (B) into the subendothelial tissue. Mean 6 SEM of 8 mice per group. *P , .05, **P , .01, ***P , .001 vs the respective vehicle group. Blood was collected from sham mice or animals subjected to 30-min clamping of the superior mesenteric artery followed by 90-min IR. Some mice received ASA (100 mg/kg orally 1 h before beginning of ischemia). Plasma was prepared and analyzed for eicosanoids content using specific enzyme immunoassays (see "Methods" vasculoprotective circuit centered on LXA 4 is activated through a neutrophil event and requires Fpr2/3 ( Figure 6 ), whereas we could not obtain evidence for an involvement of SAA or AnxA1. We therefore propose a model in which ischemia initially leads to some sort of neutrophil activation, favoring the formation of aggregates with platelets; this phenomenon would provide biosynthesis of LXA 4 , which would then act on its receptor Fpr2/3, as a relay mechanism, to control the extent of the host vascular response ( Figure 6 ). In favor of this mechanism is the notion that ischemia can indeed activate circulating neutrophils, as shown a few years ago with rat CD11b expression in myocardial infarct. 12 This cell type will become fully activated following reperfusion. 25, 38 We cannot exclude the notion that other endogenous Fpr2/3 agonists could be involved in this initial response. Potential candidates could be neutrophil-derived peptides generated from cathelicidin 39 or systemically generated ligands such as humanin. 8 Future studies will investigate this aspect. The MS results validated the changes in plasma LXA 4 during ischemia and provided a degree of specificity because levels of cognate bioactive lipids such as LXB 4 or LTB 4 were unaltered. Analysis of HETE species revealed augmented levels of 15-HETE in ischemia over sham animals, yet this change occurred in both genotypes to an equal extent. This result indicates that the low LXA 4 levels we quantified in ischemic plasma of Fpr2/3 2/2 mice are not due to enzymatic failure of the biosynthetic pathway, but rather to inadequate formation of platelet/PMN aggregates.
We concluded this series of experiments by testing whether this novel circuit could be activated by ASA. This compound can activate multiple mechanisms besides cyclo-oxygenase inhibition, including interference with transcription factor or adenosine signaling. 40 ASA is known to trigger generation of 15-epi-LXA 4 after acetylation of cyclo-oxygenase 2 catalytic site 22, 24 and can also augment native LXA 4 synthesis by shunting arachidonate metabolism toward the 5-lipoxygenase pathway. 6 In any case, ASA can exert anti-inflammatory properties via LXA 4 generation 20 as shown in experimental settings and confirmed in human investigational studies, 41 ,42 yet reliance on endogenous LXA 4 by ASA in ischemia has scarcely been studied. A recent investigation in patients undergoing abdominal aortic aneurysm surgery revealed lipid-based stratification between pro-inflammatory and proresolving phenotypes. 43 Here we compared ASA with indomethacin, another cyclo-oxygenase inhibitor unable to shunt of the catalytic activity of the enzyme. Application of full dose-responses revealed that ASA could jumpstart the mechanism we have uncovered here, by initiating 15-epi-LXA 4 synthesis, which would then act on Fpr2/3 7, 11 to inhibit the post-reflow inflammatory events within the mesenteric microcirculation (Figure 6) . At the highest doses tested, ASA acted in an Fpr2/3-independent fashion, likely by altering the generation of prostanoids and/or engaging multiple disparate pathways. 44 We would like to propose that similar events may underlie the efficacy of statins in IR settings, because these drugs can trigger 15-epi-LXA 4 synthesis after cysteine S-nitrosylation of cyclo-oxygenase-2, 45 reviewed previously. 46 Figure 6. Fpr2/3 governs LXA 4 biosynthesis and downstream inflammatory responses in the microcirculation during ischemia and reflow. Ischemic episodes led to an Fpr2/3-mediated formation of platelet/PMN aggregates, with a signal starting from the receptor expressed on the leukocyte. Aggregates afford the transcellular biosynthesis of LXA 4 via the concerted action of 5-lipoxygenase (5-LOX) and 12/15-LOX, in PMN and platelet, respectively. High levels of LXA 4 assured an appropriate (physiological) vascular inflammation during reperfusion (that subsides within 3-4 hours; not shown). Inappropriate aggregate formation during ischemia leads to low LXA 4 levels, with consequent higher degree of leukocyte adhesion and extravasation during reperfusion (reflow). The effector functions of LXA 4 on vascular inflammation processes are also mediated by Fpr2/3, because they are absent in mice deficient for this receptor. Among several mechanisms, acetylation of cyclo-oxygenase-2 (COX2) by ASA jumpstarts this protective circuit, with formation of 15-epi-LXA 4 , activating Fpr2/3 and moderating vascular reactivity. In summary, mouse Fpr2/3 and, we propose its human counterpart ALX/FPR2, governs the extent of vascular inflammation in conditions of occlusion and reflow, by promoting formation of LXA 4 , and also mediating the direct effects of this bioactive lipid mediator on leukocyte adhesion and emigration.
In conclusion, neutrophil Fpr2/3 fulfils a crucial function in vascular inflammation. Besides transducing the pharmacological properties of LXA 4 and AnxA1 in ischemia-perfusion injury, 10 this homeostatic G protein-coupled receptor becomes engaged during the early ischemic phase by governing the interaction between circulating neutrophils and platelet ( Figure 6 ). Platelet/neutrophil aggregates peak at the occlusion of the superior mesenteric artery and predispose to a "proper controlled" vascular inflammatory response that subsides within 2 to 3 hours. In the absence of Fpr2/3, an aberrant inflammatory response takes place because of, at least in part, the inadequate production of LXA 4 that is characterized by prolonged neutrophil adhesiveness and infiltration. It is plausible that this vasculoprotective circuit we describe here might be operative in other ischemic events in which rapid generation of LXA 4 occurs to avoid harmful overshooting of the host response.
